A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Clinical trial NCT07241416 · RECRUITING

Trial details

NCT number: NCT07241416
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Start date: 2025-12-05
Primary completion: 2027-03-01
Enrollment: 206

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.